Business
Trading Update
Trading Update.
About this update from Advanced Medical Solutions Group Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 3219L\n Advanced Medical Solutions Grp PLC\n 12 January 2021\n \n \n \n \n 12 January 2021\n \n \n \n Advanced Medical Solutions Group plc\n \n \n (\"AMS\" or the \"Group\")\n \n \n \n \n \n Year End Trading Update\n \n \n \n \n \n \n \n \n Winsford, UK - 12 January 2021: \n Advanced Medical Solutions Group plc (AIM: AMS), the surgical and advanced woundcare specialist company, today announces a trading update for the year ended 31 December 2020. The Group intends to publish its preliminary results for the year ended 31 December 2020 on 17 March 2021.\n \n \n \n \n \n AMS announces that FY 2020 trading has been in line with previously issued guidance. Adjusted profit before tax is expected to be slightly ahead of consensus market forecasts and revenue is expected to be slightly below consensus market forecasts at approximately £86.5 million. \n \n \n \n \n \n Despite the challenges presented by the pandemic, AMS met the demand of its healthcare partners throughout 2020 whilst prioritising the safety of its employees and maintaining its robust balance sheet. The restrictions relating to the COVID-19 pandemic during 2020 severely disrupted the entire global market and resulted in a significant slowdown in surgical and wound treatment volumes. In addition, the reduced access to hospitals for our customers and our sales teams significantly restricted our business development activities during the year. \n The timing of when hospitals' activities can return to normalised levels is expected to be determined by progress in the various COVID-19 vaccination programmes in key markets and the associated reduction in infection rates and hospital admissions. \n \n \n \n \n \n US LiquiBand® performance is on track to recover strongly in 2021 driven by:\n \n \n · \n Increased share of end-market volumes in the first quarter of 2020 maintained throughout the year.\n \n \n · \n Strong order book despite current COVID-19 restrictions.\n \n \n · \n Commercial launch of LiquiBand® Rapid™ in 2021 following its approval and virtual launch in 2020, enabling a key partner to regain ground with an improved product.\n \n \n · \n The planned 2021 launch of LiquiBand® XL, which will enable AMS to compete in the treatment of large wounds and unlock further growth potential in our Liqui...